Sirius Neosight
Lyon, FR · 2 known investors
Sirius NeoSight develops a patented technology that measures cell membrane fluidity using a fluorescent molecule to detect, isolate and characterise Circulating Tumour Cells (CTCs) from blood samples. Aimed at oncologists, the technology supports early cancer detection, monitoring of recurrence and treatment resistance, and personalised therapy selection for metastatic and aggressive cancers.
BiotechHealthtechMedical Devices
Founders & leadership
Investors · 2
Frequently asked questions
- What does Sirius Neosight do?
- Sirius NeoSight develops a patented technology that measures cell membrane fluidity using a fluorescent molecule to detect, isolate and characterise Circulating Tumour Cells (CTCs) from blood samples. Aimed at oncologists, the technology supports early cancer detection, monitoring of recurrence and treatment resistance, and personalised therapy selection for metastatic and aggressive cancers.
- Who founded Sirius Neosight?
- Sirius Neosight was founded by Arnaud Vigneron, David Gueyrard, Jean-Guillaume Lafay, Stéphane Legastelois.
- Who are Sirius Neosight's investors?
- Sirius Neosight's investors include Angels Santé, Octalfa.
- Where is Sirius Neosight headquartered?
- Sirius Neosight is headquartered in Lyon, FR.